Matrifen

Fentanyl, the active ingredient in Matrifen, is an opioid analgesic presented as a transdermal patch for transdermal use. It provides continuous systemic analgesia for patients with chronic severe pain, including cancer‑related pain, when other treatments are insufficient.

GNH USA supplies Matrifen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring regulatory‑aligned sourcing and reliable delivery. The product complies with European Union pharmaceutical standards and is available for prescription use across EU member states.

Fentanyl is an opioid analgesic used in the management of severe pain conditions.

- Chronic severe pain: provides continuous analgesia for patients whose pain is not adequately controlled by other opioids. - Cancer‑related pain: alleviates persistent pain associated with malignant disease. - Breakthrough pain: used together with short‑acting opioids to manage episodic pain spikes. - Palliative care: maintains comfort in end‑of‑life settings.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel motility. - Drowsiness: increased sleepiness. - Skin irritation: redness or itching at the patch site.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Severe hypotension: marked drop in blood pressure. - Adrenal insufficiency: impaired cortisol response. - Fentanyl overdose: potentially life‑threatening toxicity.

When prescribing or using Matrifen, consider the following precautions: - Assess opioid tolerance before initiating: verify prior opioid exposure. - Monitor respiratory function: check breathing rate and oxygen saturation regularly. - Evaluate for signs of addiction: screen for misuse risk. - Avoid use in patients with severe respiratory disease: contraindicated. - Store at room temperature: keep patch in original packaging, protect from moisture and heat.

Fentanyl may interact with several drug classes.

Major Interactions (Avoid): - Concomitant CNS depressants: increased risk of respiratory depression. - MAO inhibitors: potential for severe hypotension. - CYP3A4 inhibitors (e.g., ketoconazole): may raise fentanyl plasma levels.

Moderate Interactions (Monitor Closely): - Benzodiazepines: additive sedation and respiratory effects. - Alcohol: enhances central nervous system depression. - Anticholinergics: may worsen constipation.